National Research Corporation Reports Mixed Q2 2025 Results Amid Revenue Decline and New Leadership

National Research Corporation (NASDAQ: NRC) recently released its Q2 2025 financial statements, providing insight into its operational performance and financial health. Complex market conditions and strategic decisions have culminated in a mixed financial outcome for the corporation.

Income Statement Highlights:

• Q2 2025 Revenue: $34,038,000 (down 3% from Q2 2024, which was $35,021,000)
• Operating Income: $1,588,000 (down 82% from Q2 2024's $8,865,000)
• Net Loss: $(106,000) compared to net income of $6,175,000 in Q2 2024
• Earnings per Share: Basic $(0.01); diluted $(0.01)

Positive Aspects:

• Increase in cash and equivalents: $5,274,000, up from $4,233,000 in 2024.
• Direct expenses decreased slightly from $13,422,000 in Q2 2024 to $12,974,000.
• Strong performance from new clients contributing an additional $419,000 in revenue.
• Total Recurring Contract Value (TRCV) increased sequentially, indicating potential revenue growth ahead.

Negative Aspects:

• Overall revenue decline primarily driven by reduced recurring revenue from existing clients, decreasing by $1,300,000.
• Significant rise in selling, general, and administrative expenses, up 58% year-over-year to $17,734,000.
• Operating margin fell to 5%, down from 25% in the previous year.
• Effective tax rate increased to 118% due to executive compensation deductibility limits.

Key Financial Statistics:

• Total Assets: $141,387,000, up from $132,539,000
• Total Liabilities: $120,059,000, compared to $101,255,000 the previous year
• Shareholders' Equity: $21,328,000, down from $31,284,000
• Cash Flow from Operating Activities: $5,507,000, down significantly from $18,824,000

The corporation's appointment of a new CEO, Trent Green, brings hope for strategic revitalization. However, the notable net loss and increasing operating expenses amid a decrease in revenue raise concerns about long-term profitability. Investors will look for signs of stabilization in the upcoming quarters as the company seeks to leverage its strengthened cash position and adapt to the evolving healthcare landscape.